Pyxis Oncology (PYXS) Income from Non-Controlling Interests (2023 - 2025)
Pyxis Oncology's (PYXS) quarterly Income from Non-Controlling Interests came in at $675000.0 in Q4 2025, down 5.46% year-on-year from $714000.0 in Q4 2024, and down 3.57% on a QoQ basis from $700000.0 in Q3 2025.
Pyxis Oncology (PYXS) Income from Non-Controlling Interests (2023 - 2025) Analysis & Trends
Pyxis Oncology (PYXS) has 3 years of Income from Non-Controlling Interests data on file, last reported at $675000.0 in Q4 2025.
- On a quarterly basis, Income from Non-Controlling Interests fell 5.46% year-over-year to $675000.0 in Q4 2025; TTM through Dec 2025 was $2.6 million, a 12.15% decrease from a year earlier, with the FY2025 full-year figure at $2.6 million, down 12.0% from the prior year.
- Income from Non-Controlling Interests for Q4 2025 stood at $675000.0, down from $700000.0 in the prior quarter.
- Over the last five years, Income from Non-Controlling Interests for PYXS reached as high as $799000.0 in Q1 2024 and fell as low as $38000.0 in Q1 2023.
- Historically, Income from Non-Controlling Interests has averaged $606166.7 across 3 years, with a median of $679500.0 in 2025.
- Across the five-year window, Income from Non-Controlling Interests soared 2002.63% in 2024 and tumbled 37.42% in 2025, its largest moves.
- Year by year, Income from Non-Controlling Interests stood at $600000.0 in 2023, then gained by 19.0% to $714000.0 in 2024, then fell by 5.46% to $675000.0 in 2025.
- Per Business Quant data, the three most recent Income from Non-Controlling Interests figures were $675000.0 in Q4 2025, $700000.0 in Q3 2025, and $684000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,320.50 Bn | 66,320.21 Bn | - | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.93 Bn | 468.14 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 122.22 Bn | 114.98 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.96 Bn | 61.21 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - | - |
| 8 | Argenx Se | 56.07 Bn | 50.89 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.60 Bn | 34.59 Bn | 959.66 Mn | - |
| 10 | Pyxis Oncology | 181.46 Mn | 114.60 Mn | 8.65 Mn | 675,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 675,000.00 |
| Sep 30, 2025 | 700,000.00 |
| Jun 30, 2025 | 684,000.00 |
| Mar 31, 2025 | 500,000.00 |
| Dec 31, 2024 | 714,000.00 |
| Sep 30, 2024 | 700,000.00 |
| Jun 30, 2024 | 700,000.00 |
| Mar 31, 2024 | 799,000.00 |
| Dec 31, 2023 | 600,000.00 |
| Sep 30, 2023 | 600,000.00 |
| Jun 30, 2023 | 564,000.00 |
| Mar 31, 2023 | 38,000.00 |